Cumulative evidence shows that GLP-1 exerts direct and beneficial effects on hepatocytes to protect against the progression of NAFL to NASH, suggesting that GLP-1 could be a novel therapy for NASH14–17. The gene discussed is GLP1R; the disease is non-alcoholic fatty liver.